Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.96 USD | +15.29% | +13.95% | +240.87% |
May. 15 | Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study | MT |
May. 14 | Transcript : Ocugen, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+240.87% | 504M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- OCGN Stock
- News Ocugen, Inc.
- Ocugen to Restate Financial Statements; Shares Tumble